The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy

Clinical Journal of the American Society of Nephrology - United States
doi 10.2215/cjn.03130411
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Nephrology (ASN)

Related search

Psy23 - Agalsidase Alfa and Agalsidase Beta for Treatment of Fabry Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparison of the Effects of Agalsidase Alfa and Agalsidase Beta on Cultured Human Fabry Fibroblasts and Fabry Mice

Journal of Human Genetics
Genetics
2005English

Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase Beta Therapy in Patients With Fabry Disease

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2007English

Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2017English

Biventricular Cardiomyopathy Improvement by Shifting Therapy From Agalsidase Alfa to Agalsidase Beta in Anderson-Fabry Disease (RCD Code: III-3B.2)

Journal of Rare Cardiovascular Diseases
Cardiovascular MedicineCardiology
2018English

Long-Term Antihypertensive Treatment Inhibiting Progression of Diabetic Nephropathy

BMJ
1982English

Limited Effects of Long-Term Enzyme Replacement Therapy on the Cardiac Conduction System in Fabry Disease

Journal of Cardiology Cases
Cardiovascular MedicineCardiology
2018English

Cost/Effectiveness of Aripiprazole vs. Olanzapine in the Long-Term Treatment of Schizophrenia

Srpski Arhiv Za Celokupno Lekarstvo
Medicine
2019English

Long-Term Efficacy of Tonsillectomy as a Treatment for IgA Nephropathy

Journal of Japan Society of Immunology & Allergology in Otolaryngology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy